455 — Tianda Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- HK$208.55m
- HK$276.12m
- HK$322.95m
Annual cashflow statement for Tianda Pharmaceuticals, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -27.4 | -28 | -25.7 | -54.3 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -3.96 | -11.3 | 2.08 | 2.47 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -26.8 | 8.91 | -62.5 | 3.94 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -37.6 | -8.23 | -49.8 | -9.7 | — |
| Capital Expenditures | -146 | -46.5 | -65.9 | -42.6 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 8.72 | 133 | -3.2 | 10.8 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -138 | 86.3 | -69.1 | -31.8 | — |
| Financing Cash Flow Items | -6.94 | -0.887 | -25.2 | 0 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 90.8 | -1.29 | -57.4 | -30.6 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -63.7 | 85.8 | -178 | -76.8 | — |